Novo Nordisk outlines strategy to expand beyond diabetes and obesity drugs
Novo Nordisk CEO Mike Doustdar presented a new growth plan at a capital markets day in London on Monday.
Plans for future product launches
The company intends to launch at least five major products by the year 2030. Management aims to sell these items more like consumer goods than traditional medicines.
Investment in new disease areas
Leaders stated they will invest more heavily in conditions outside of diabetes and obesity. The firm also plans to become more active within business development to address investor concerns about reliance on current GLP-1 drugs.
Market reaction to the announcement
Shares for the pharmaceutical company dropped 5 percent during the opening remarks of the event. Investors sought more specific details regarding the new strategy before the market closed.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.